entertainment -WSS

entertainment

author：Wikipedia 2025-09-06 01:57:46 - browse：5

Lung cancer under microscope — coverage from STAT — Lung cancer Adobe

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the design of a key clinical trial.

Delfi also announced that the Merck Global Health Innovation Fund, the VC arm of the drug giant, has made an investment of an undisclosed amount in the company.

Unlike Grail, a unit of Illumina, or Exact Sciences, which seeks to develop a blood test that can be used to screen for multiple types of cancer, Delfi is focusing on a single disease — lung cancer — in which the utility of screening with existing technology is not in dispute. Using low-dose CT scans to detect lung cancer is considered an established technology for people at higher risk of lung cancer. However, far too few people get screened.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： STAT Readout Newsletter: Biotech news today

WSS

The problems with dementia villages

Listen: Wegovy in the brain & pivotal Alzheimer's data

Listen: Wegovy in the brain & pivotal Alzheimer's data

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

STAT Summit: How researchers deal with rejection

Listen: Wegovy in the brain & pivotal Alzheimer's data

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Health tech investors get more selective as pandemic boom fades

Jerome Adams on the need for new antivirals for Covid

Listen: Wegovy in the brain & pivotal Alzheimer's data

Jerome Adams on the need for new antivirals for Covid

Cosmetics set for new safety regulation. Why the industry is on board

Supreme Court strikes down use of affirmative action

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: Live from the 2023 STAT Summit

focus

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

CZI to create biohub to build anti

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Roche drug slashes death risk in early

Sanders adds drug shortage policies to pandemic preparedness bill

hotspot

focus

focus

hotspot